BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cancer Vaccine Company DCPrime Appoints Marcel Zwaal CEO, and Dr. Anthony Hall CMO and Expands Supervisory Board


10/9/2012 7:13:20 AM

LEIDEN, The Netherlands--(BUSINESS WIRE)-- Cancer vaccine company DCPrime today announced the appointments of Marcel Zwaal as Chief Executive Officer, and of Dr. Anthony Hall as Chief Medical Officer. Dr. Anthony Hall has 18 years of experience in clinical drug development, in particular in orphan drug indications. Dr. Ada Kruisbeek, founder of DCPrime and since the start of the company active in a dual role as CEO and Chief Scientific Officer, will continue to build and expand the company’s product platform technology as CSO.

“DCPrime is entering a new stage of its development with an on-going Phase I/IIa trial in Acute Myeloid Leukemia and a Phase II efficacy trial to start in the course of 2013,” said Michel Briejer, Chairman of DCPrime’s Supervisory Board. “With Marcel stepping up from Chief Business Officer to the position of CEO, Ada focusing on reinforcing and expanding the platform, and Tony joining to move our clinical programs forward, DCPrime has a formidable team in place to bring the company’s exciting new class of off-the-shelf cancer vaccines to market.”

DCPrime also appointed Bart Klein to its Supervisory Board. Mr. Klein, former Executive Vice President Intellectual Property & Legal Affairs at Crucell, brings 23 years of experience in intellectual property and licensing. In addition to Mr. Klein, the Supervisory Board consists of Onno van de Stolpe, CEO of Galapagos, Dr. Herbert Heyneker, one of the most distinguished scientist entrepreneurs in the biotech industry, Dr. Leon Hooftman who, following a high-profile career in clinical development, currently is Chief Medical Officer of Synthon, and Dr. Michel Briejer, chairman and partner of Thuja Capital, DCPrime’s cornerstone investor.

“I am delighted to take the helm from Ada, and be given the opportunity to lead the charge to bring DCPrime’s cancer vaccines to patients with real unmet medical needs,” said Marcel Zwaal, CEO. “Supported by our dedicated board members, our management team now has all the capabilities to make a push forward, and capitalize on our first-in-class product platform to develop effective cancer vaccines.”

About DCPrime

DCPrime develops off-the-shelf dendritic cell-based vaccines for a broad range of cancer types, based on its unique, proprietary technology platform, DCOne™. DCOne-based dendritic cell vaccines, in some indications loaded with cancer antigens for targeted treatment, are used as standardized, therapeutic products. The platform combines the power of dendritic cell-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products. DCPrime has a commercial scale manufacturing process for DCOne-based vaccines in place, and the company’s lead product DCP-001 is in the clinic in a Phase I/IIa study in patients with Acute Myeloid Leukemia (AML). Several products for solid cancers are in preclinical development, using peptide loaded DCOne-based vaccines.

Contact:

DCPrime

Marcel Zwaal, CEO, +31 71 3322627

m.zwaal@dcprime.nl

or

Capricorn One

Hans Herklots, +41 79 598 7149

capricorn1@bluewin.ch



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES